Literature DB >> 25589930

Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.

Nicole C Goodwin1, Giovanni Cianchetta1, Hugh A Burgoon1, Jason Healy1, Ross Mabon1, Eric D Strobel1, Jason Allen2, Shuli Wang2, Brian D Hamman2, David B Rawlins1.   

Abstract

The first allosteric, type III inhibitor of LIM-kinase 2 (LIMK2) is reported. A series of molecules that feature both an N-phenylsulfonamide and tertiary amide were not only very potent at LIMK2 but also were extremely selective against a panel of other kinases. Enzymatic kinetic studies showed these molecules to be noncompetitive with ATP, suggesting allosteric inhibition. X-ray crystallography confirmed that these sulfonamides are a rare example of a type III kinase inhibitor that binds away from the highly conserved hinge region and instead resides in the hydrophobic pocket formed in the DFG-out conformation of the kinase, thus accounting for the high level of selectivity observed.

Entities:  

Keywords:  DFG-out; LIM kinase 2; allosteric; noncompetitive; selective; type III kinase inhibitor

Year:  2014        PMID: 25589930      PMCID: PMC4291701          DOI: 10.1021/ml500242y

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  20 in total

Review 1.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

Review 2.  Determining the chemical mechanisms of enzyme-catalyzed reactions by kinetic studies.

Authors:  W W Cleland
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1977

3.  Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.

Authors:  Masanori Okaniwa; Masaaki Hirose; Takashi Imada; Tomohiro Ohashi; Youko Hayashi; Tohru Miyazaki; Takeo Arita; Masato Yabuki; Kazuyo Kakoi; Juran Kato; Terufumi Takagi; Tomohiro Kawamoto; Shuhei Yao; Akihiko Sumita; Shunichirou Tsutsumi; Tsuneaki Tottori; Hideyuki Oki; Bi-Ching Sang; Jason Yano; Kathleen Aertgeerts; Sei Yoshida; Tomoyasu Ishikawa
Journal:  J Med Chem       Date:  2012-03-14       Impact factor: 7.446

4.  Identification of type II and III DDR2 inhibitors.

Authors:  André Richters; Hoang D Nguyen; Trang Phan; Jeffrey R Simard; Christian Grütter; Julian Engel; Daniel Rauh
Journal:  J Med Chem       Date:  2014-05-05       Impact factor: 7.446

5.  A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors.

Authors:  A Cornish-Bowden
Journal:  Biochem J       Date:  1974-01       Impact factor: 3.857

Review 6.  Lim kinases, regulators of actin dynamics.

Authors:  Ora Bernard
Journal:  Int J Biochem Cell Biol       Date:  2006-11-28       Impact factor: 5.085

7.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

8.  A novel method for measurement of submembrane ATP concentration.

Authors:  F M Gribble; G Loussouarn; S J Tucker; C Zhao; C G Nichols; F M Ashcroft
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

9.  Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.

Authors:  Bryce A Harrison; N Andrew Whitlock; Michael V Voronkov; Zheng Y Almstead; Kun-jian Gu; Ross Mabon; Michael Gardyan; Brian D Hamman; Jason Allen; Suma Gopinathan; Beth McKnight; Mike Crist; Yulian Zhang; Ying Liu; Lawrence F Courtney; Billie Key; Julia Zhou; Nita Patel; Phil W Yates; Qingyun Liu; Alan G E Wilson; S David Kimball; Craig E Crosson; Dennis S Rice; David B Rawlins
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

10.  The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.

Authors:  Justin Dietrich; Christopher Hulme; Laurence H Hurley
Journal:  Bioorg Med Chem       Date:  2010-06-04       Impact factor: 3.641

View more
  20 in total

1.  Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.

Authors:  Kumar Nikhil; Lei Chang; Keith Viccaro; Max Jacobsen; Callista McGuire; Shakti R Satapathy; Michael Tandiary; Meaghan M Broman; Gregory Cresswell; Yizhou J He; George E Sandusky; Timothy L Ratliff; Dipanjan Chowdhury; Kavita Shah
Journal:  Cancer Lett       Date:  2019-02-01       Impact factor: 8.679

Review 2.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

3.  Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.

Authors:  Bryce A Harrison; Zheng Y Almstead; Hugh Burgoon; Michael Gardyan; Nicole C Goodwin; Jason Healy; Ying Liu; Ross Mabon; Brett Marinelli; Lakshman Samala; Yulian Zhang; Terry R Stouch; N Andrew Whitlock; Suma Gopinathan; Beth McKnight; Shuli Wang; Nita Patel; Alan G E Wilson; Brian D Hamman; Dennis S Rice; David B Rawlins
Journal:  ACS Med Chem Lett       Date:  2014-11-24       Impact factor: 4.345

4.  Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.

Authors:  Yan Yin; Ke Zheng; Nibal Eid; Shannon Howard; Ji-Hak Jeong; Fei Yi; Jia Guo; Chul Min Park; Mathieu Bibian; Weilin Wu; Pamela Hernandez; HaJeung Park; Yuntao Wu; Jun-Li Luo; Philip V LoGrasso; Yangbo Feng
Journal:  J Med Chem       Date:  2015-02-04       Impact factor: 7.446

5.  Suppression of LIM Kinase 1 and LIM Kinase 2 Limits Glioblastoma Invasion.

Authors:  Joseph Chen; Badriprasad Ananthanarayanan; Kelsey S Springer; Kayla J Wolf; Sharon M Sheyman; Vivien D Tran; Sanjay Kumar
Journal:  Cancer Res       Date:  2019-10-22       Impact factor: 12.701

6.  Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome.

Authors:  Risa Kashima; Patrick L Redmond; Prajakta Ghatpande; Sougata Roy; Thomas B Kornberg; Thomas Hanke; Stefan Knapp; Giorgio Lagna; Akiko Hata
Journal:  Sci Signal       Date:  2017-05-02       Impact factor: 8.192

7.  Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

Authors:  Alexei S Karpov; Payman Amiri; Cornelia Bellamacina; Marie-Helene Bellance; Werner Breitenstein; Dylan Daniel; Regis Denay; Doriano Fabbro; Cesar Fernandez; Inga Galuba; Stephanie Guerro-Lagasse; Sascha Gutmann; Linda Hinh; Wolfgang Jahnke; Julia Klopp; Albert Lai; Mika K Lindvall; Sylvia Ma; Henrik Möbitz; Sabina Pecchi; Gabriele Rummel; Kevin Shoemaker; Joerg Trappe; Charles Voliva; Sandra W Cowan-Jacob; Andreas L Marzinzik
Journal:  ACS Med Chem Lett       Date:  2015-05-22       Impact factor: 4.345

8.  Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.

Authors:  Kumar Nikhil; Mohini Kamra; Asif Raza; Kavita Shah
Journal:  Cancer Lett       Date:  2020-09-12       Impact factor: 8.679

9.  LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer.

Authors:  Moloud A Sooreshjani; Kumar Nikhil; Mohini Kamra; Dung N Nguyen; Dinesh Kumar; Kavita Shah
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

Review 10.  Progress in the therapeutic inhibition of Cdc42 signalling.

Authors:  Natasha P Murphy; Helen R Mott; Darerca Owen
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.